Ventria Bioscience
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (June 2019) |
 | |
| Company type | Private company |
|---|---|
| Industry | Biotechnology |
| Founded | 1993 |
| Headquarters | Fort Collins, CO |
Area served | United States |
| Products | Bioscience Products |
| Website | www.ventria.com |
Ventria Bioscience is a biotech company with a focus on human nutrition and human therapeutics. The company was established in 1993 in Colorado.[1] The company's core technology is a genetically modified crop-based protein production system (also called a "pharming" system) called ExpressTec.
ExpressTec uses self-pollinating crops such as rice and barley to minimize the risk of gene flow normally associated with transgenic plants. Plant-produced proteins also offer advantages for cell culture and bioprocessing use because they replace animal derived components, which have become unpopular due to concerns about prion contamination.[citation needed]
Facilities
Ventria's corporate headquarters is in Fort Collins, Colorado, with additional facilities in Kansas. On September 29, 2006, Kansas officials announced an agreement to bring Ventria’s new bioprocessing facility to Junction City, Kansas. Kansas Governor Kathleen Sebelius was very supportive of the agreement and was quoted as stating "I welcome Ventria Bioscience to Kansas and look forward to their contributions to the health of children worldwide."[2] The effort to attract Ventria to Kansas involved a number of players, including Governor Kathleen Sebelius, Secretary of Agriculture Adrian Polansky, The Kansas Department of Commerce, Junction City and Geary County, Kansas Technology Enterprise Corporation (KTEC), KansasBIO, Kansas State University, and Kansas Farm Bureau.
Markets and products
As of 2012 Ventria is developing six therapeutic products:
- Human Health
- VEN100 Recombinant human lactoferrin for antibiotic-associated diarrhea[3]
- VEN101 for Chemotherapy-Induced Diarrhea[4]
- VEN120 for Inflammatory Bowel Disease[5]
- VEN130 for Osteoporosis[6]
- VEN140 for Hepatic disease[7]
- VEN200 Optibumin Recombinant human albumin as a replacement for therapeutic human serum albumin[8]
The company offers contract biomanufacturing services using its ExpressTec platform, and, through its subsidiary InVitria, sells a line of its proteins that it manufactures for the life sciences research market.[9]
The company is conducting research in the field of zoonotic disease, specifically in lyme disease and rabies, with a goal of developing vaccines and offers some its recombinant proteins to life sciences researchers under a program called BioShare.[10]
See also
References
- ^ Bloomberg BusinessWeek - Ventria Bioscience, Inc.
- ^ "Kansas Bio" (PDF).
- ^ Ventria VEN100 page
- ^ Ventria VEN101 page
- ^ Ventria VEN120 page
- ^ Ventria VEN130 page
- ^ Ventria VEN140 information on pipeline page
- ^ Ventria VEN200 page
- ^ InVitria Official Website
- ^ "BioShare | Research Collaborations with Ventria Bioscience".
External links
- Pharmaceutical companies of the United States
- Biotechnology companies of the United States
- Privately held companies based in Colorado
- Companies based in Fort Collins, Colorado
- Pharmaceutical companies established in 1993
- Biotechnology companies established in 1993
- Health care companies based in Colorado
- 1993 establishments in Colorado